SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2022 / Cilt: 70 - Sayı: 1

Current treatment of systemic sclerosisassociated interstitial lung disease

Sistemik sklerozis ilişkili interstisyel akciğer hastalığının güncel tedavisi

Erdoğan ÇETİNKAYA
Cemal BEŞ
Pages
85–92
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This article will also review the current treatment options of SSc-ILD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Systemic sclerosis (SSc) is a connective tissue disease characterized by immune irregularity, vasculopathy and excessive collagen production, which causes skin and internal organ fibrosis.
📊
Key Findings & Data:Although SSc often affects multiple organs and/or systems, lung involvement and especially interstitial lung disease (ILD) are the leading cause of death in this disease.
💡
Conclusion & Impact:This article will also review the current treatment options of SSc-ILD.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Systemic sclerosis (SSc) is a connective tissue disease characterized by immune irregularity, vasculopathy and excessive collagen production, which causes skin and internal organ fibrosis. Although SSc often affects multiple organs and/or systems, lung involvement and especially interstitial lung disease (ILD) are the leading cause of death in this disease. The fact that different treatment options have been raised in recent years has given hope to clinicians in the management of this disease. This article will also review the current treatment options of SSc-ILD.

Özet

Sistemik skleroz (SSc), deri ve iç organ fibrozisine neden olan ve vaskülopati, immün sistem işlev bozukluğu ile giden bir bağ dokusu hastalığıdır. Sistemik skleroz, sıklıkla birden fazla organı ve/veya sistemi etkilese de akciğer tutulumu ve özellikle de interstisyel akciğer hastalığı (İAH) bu hastalıkta önde gelen ölüm nedenidir. Son yıllarda farklı tedavi seçeneklerinin olması bu hastalığın yönetiminde klinisyenlere umut vermiştir. Bu makalede SSc-İAH’nin güncel tedavi seçenekleri gözden geçirilecektir.

🔖

Cite This Article

ÇETİNKAYA, E., BEŞ, C. (2022). Current treatment of systemic sclerosisassociated interstitial lung disease. Tüberküloz ve Toraks, Cilt: 70 - Sayı: 1, 85–92. https://ajindex.com/articles/618272

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demograhic, clinical, and serologic features and survival in 1012 Italian patients. Medicine 2002
  2. 81(2): 139-53. https://doi. org/10.1097/00005792-200203000-00004 2. Steele R, Hudson M, Lo E, Baron M. Canadian scleroderma research group. Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. Arthritis Care Res (Hoboken) 2012
  3. https://doi.org/10.1002/acr.21583 3. Firestein GS, Budd RC, Harris ED Jr. McInnes IB, Ruddy S. (eds). Kelley’s Textbook of Rheumatology. Volume II. 2005. p.1279-303. 4. Harrison NK, Myers AR, Corin B, Soosay G, Dewar A, Black CM, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991
  4. https://doi.org/10.1164/ajrccm/144.3_Pt_1.706 5. Hayman LD, Hunt RE. Pulmonary fibrosis in generalized scleroderma. Dis Chest 1952
  5. https://doi. org/10.1378/chest.21.6.691 6. Kahaleh MB. Endothelin, an endothelial-dependendent vasoconstrictor in scleroderma. Arthritis Rheum 1991
  6. https://doi.org/10.1002/art.1780340807 7. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993
  7. https://doi.org/10.1016/0140-6736(93)90694-C 8. Silver RM, Metcalf JF, Sranley JH, LeRoy EC. Interstitial lung disease in scleroderma. Arthritis Rheum 1984
  8. https://doi.org/10.1002/art.1780271107 9. Ohba T, McDonald JK, Silver RM, Strange C, LeRoy EC, Ludwicka A. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha receptor. Am J Respir Cell Mol Biol 1994
  9. 10(4): 405-12. https://doi.org/10.1165/ajrcmb.10.4.7510986 10. Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor mediated production of TGF-beta1. Am J Respir Cell Mol Biol 2007
  10. 37(1): 38-47. https://doi. org/10.1165/rcmb.2006-0353OC 11. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987
  11. 247(3): 597-604. https://doi. org/10.1042/bj2470597 12. Shi Wen X, Rodríguez Pascual F, Lamas S